Latest stories on DNLI
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Quartz58 · neutralgeneral
Denali Therapeutics price target raised to $35 from $30 at B. Riley
The Fly61 · neutralanalyst
Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story
TipRanks53 · neutralearnings
Denali Therapeutics: Bullish On Avlayah And Their Prospects
Seeking Alpha63 · neutralanalyst
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
The Motley Fool59 · neutralearnings
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Seeking Alpha73 · bullishproduct/pr
Denali Therapeutics Price Target Raised To 34 From 25 At Ubs
The Fly61 · neutralanalyst
Denali Therapeutics Price Target Raised To 34 From 31 At Baird
The Fly61 · neutralanalyst
Denali expects $10M-$12M in Q3 AVLAYAH net product revenue as launch momentum builds
Seeking Alpha67 · bullishproduct/pr
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Denali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Denali Therapeutics Reports Q2 Eps 68c Consensus 47c
The Fly73 · bullishearnings
Denali Therapeutics Inc. (DNLI) files 8-K
SEC 8-K50 · neutralgeneral
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
StockTitan50 · neutralearnings
Denali Therapeutics Sells Priority Review Voucher for Capital
TipRanks24 · bearishgeneral
Denali Therapeutics Inc. (DNLI) files 8-K
SEC 8-K50 · neutralgeneral
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
StockTitan50 · neutralgeneral
Q&A: Natalie Wolfsen on Orion's AI Strategy and Platform Growth
Yahoo Finance63 · neutralproduct/pr
As U.S. Farmers Struggle with Fertilizer Access and Affordability, Denali Offers Natural Alternative to Reduce Input Costs
Business Insider58 · neutralproduct/pr
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
TipRanks63 · neutralproduct/pr
Denali to sell priority review voucher for $195M
Seeking Alpha63 · neutralgeneral
Denali Monetizes FDA Voucher to Advance CNS Pipeline
TipRanks63 · neutralproduct/pr
Denali Therapeutics Inc. (DNLI) files 8-K
SEC 8-K50 · neutralgeneral